VM

Venkata Mohana Krishna Gollapudi

Active Director Director DIN 10643121
DIN 10643121 First appointment May 2024 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Venkata Mohana Krishna Gollapudi

Data last updated:

Venkata Mohana Krishna Gollapudi is a Director at Purekem Pharmaceuticals Private Limited (since 2024). The company operates in Pharma.

DIN 10643121
Primary Designation Director
Industry Pharma
First Appointment 24 May 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director24 May 20242024Active

Board colleagues of Venkata Mohana Krishna Gollapudi

NameDINCompanyDesignation
Anusha Popuri10643122Purekem Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Purekem Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Venkata Mohana Krishna Gollapudi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Venkata Mohana Krishna Gollapudi

Venkata Mohana Krishna Gollapudi currently holds 1 directorship: Purekem Pharmaceuticals Private Limited (Director, since 24 May 2024).

Venkata Mohana Krishna Gollapudi was first appointed on 24 May 2024 as Director at Purekem Pharmaceuticals Private Limited.

The current boards of Venkata Mohana Krishna Gollapudi's companies include Anusha Popuri (Purekem Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available